Stock Buybacks (Quarterly) Chart

View Stock Buybacks (Quarterly) for IONS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Stock Buybacks (Quarterly) Chart
Start Trial

Historical Stock Buybacks (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 -20.26M
March 31, 2026 -57.30M
December 31, 2025 -107.82M
September 30, 2025 -81.26M
June 30, 2025 -1.287M
March 31, 2025 -2.241M
December 31, 2024 -0.429M
September 30, 2024 -496.10M
June 30, 2024 -2.596M
March 31, 2024 -23.61M
December 31, 2023 -40.76M
September 30, 2023 -3.73M
June 30, 2023 -2.39M
March 31, 2023 -2.56M
December 31, 2022 -0.343M
September 30, 2022 -2.568M
June 30, 2022 -1.614M
March 31, 2022 -1.848M
December 31, 2021 15.61M
September 30, 2021 -1.922M
June 30, 2021 -91.63M
March 31, 2021 -7.76M
December 31, 2020 -22.59M
September 30, 2020 -13.00M
June 30, 2020 -8.803M
Date Value
March 31, 2020 82.90M
December 31, 2019 -29.24M
September 30, 2019 -10.13M
June 30, 2019 -34.95M
March 31, 2019 -67.06M
December 31, 2018 -9.646M
September 30, 2018 -8.076M
June 30, 2018 -452.92M
March 31, 2018 -5.224M
December 31, 2017 -4.279M
September 30, 2017 -168.25M
June 30, 2017 -3.35M
March 31, 2017 -77.19M
December 31, 2016 -5.345M
September 30, 2016 -3.134M
June 30, 2016 -1.384M
March 31, 2016 -2.736M
December 31, 2015 -4.613M
September 30, 2015 -2.24M
June 30, 2015 -3.919M
March 31, 2015 -14.12M
December 31, 2014 -5.362M
September 30, 2014 -4.293M
June 30, 2014 -1.413M
March 31, 2014 -12.00M

Stock Buyback Definition

Stock buybacks are when companies buy back their own stock, removing it from the marketplace. Stock buybacks increase the value of the remaining shares because there is now less common stock outstanding and company earnings are split among fewer shares.

Read full definition.

Stock Buybacks (Quarterly) Range, Past 5 Years

View Stock Buybacks (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Stock Buybacks (Quarterly) Benchmarks

View Stock Buybacks (Quarterly) Benchmarks
Start Trial
Alnylam Pharmaceuticals, Inc. -33.56M
Biogen, Inc. -6.00M
BridgeBio Pharma, Inc. 122.28M
Vertex Pharmaceuticals, Inc. 421.80M
Arrowhead Pharmaceuticals, Inc. -29.86M